Dal-OUTCOMES (Completed)
A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients.
- Medicine
- cetp-remmer
- Population
- ASCVD
- Phase
- III
- Starting year
- 2008
- More information
- ClinicalTrials.gov